Drug Trial Radar · NCT07791758
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
369
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Sep 4, 2030
Study completion Sep 4, 2030
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Sun Yat-Sen University Cancer Center
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.
Conditions
- Metastatic Colorectal Carcinoma
Interventions
LBL-024 for InjectionDrug
intravenous infusion.
Bevacizumab injectionDrug
intravenous infusion.
Oxaliplatin injectionDrug
intravenous infusion.
Capecitabine tabletsDrug
Oral.
Fruquintinib CapsulesDrug
Oral.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)
- Occurrence of adverse event (AE) and serious adverse event (SAE)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The Sixth Affiliated Hospital Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
The First Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Shanghai GoBroad Cancer Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.